Back to today’s briefing

Story perspectives

FDA Approves First Non-Opioid Pain Relief in 20 Years

1/31/2025

47 9

Summary

Story summary

The FDA has given the green light to Journavx (suzetrigine), a groundbreaking non-opioid analgesic designed to tackle moderate-to-severe acute pain in adults. As the first new class of pain management in over two decades, this innovative treatment from Vertex Pharmaceuticals is priced at $31 per day, promising a vital alternative for those seeking relief without opioids.

1 of 1

Story summary

The FDA has given the green light to Journavx (suzetrigine), a groundbreaking non-opioid analgesic designed to tackle moderate-to-severe acute pain in adults. As the first new class of pain management in over two decades, this innovative treatment from Vertex Pharmaceuticals is priced at $31 per day, promising a vital alternative for those seeking relief without opioids.